Autologous Stem Cell Therapy in Stroke

Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Stroke

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02245698

Enrollment

Registered

2014-09-19

Start date

2008-12-31

Completion date

2018-12-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Chronic Stroke, Subacute stroke, Autologous Bone Marrow Mononuclear Cell therapy, Stem cell

Brief summary

The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with sub acute/chronic stroke.

Interventions

BIOLOGICALStem cell

Intrathecal autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age18 years-80 years * diagnosed as stroke by clinical and MRI findings

Exclusion criteria

* presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/ Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever * hemoglobin less than 8 * bleeding tendency * bone marrow disorder * left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Functional Independence Measure	1 year	Functional Independence Measure scale assesses the patients ability to carry out activities of daily living. At the follow up of 1 year, every patient in this study will be reevaluated on this scale.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026